Final Programme - iuphar

More documents

Recommendations

Info

FC07 Simulation and data modelling in drug development. Better drugs faster? Leaders: Hartmut Derendorf, (USA) FC07.3 Modelling and simulation in clinical drug development Chairs: Hans-Günter Schäfer, (Germany) & Hartmut Derendorf, (USA) 09:30 - 09:55 FC07.3.1 Modelling and simulation in clinical drug development at Boehringer Ingelheim Hans-Günter Schäfer, (Germany), A Staab 09:55 - 10:20 FC07.3.2 Modeling and simulation in clinical drug development at Bristol-Myers Squibb Amit Roy, (USA), M Pfister 10:20 - 10:45 FC07.3.3 Modelling and simulation in clinical drug development at Pfizer Sriram Krishnaswami, (USA) 10:45 - 11:15 COFFEE BREAK 11:15 - 11:40 FC07.3.4 Modelling and simulation in clinical drug development at Eli Lilly Sandra RB Allerheiligen, (USA) 11:40 - 11:55 FC07.3.5 Free Communication Presentation: Therapeutic drug monitoring and population pharmacokinetic modelling of topiramate in patients with epilepsy Mihajlo Jakovljevic, (Republic of Serbia), T Vovk, M Keres Kos, S Jankovic, A Mrhar, I Grabnar 11:55 - 12:10 FC07.3.6 Free Communication Presentation: A population pharmacokinetic study of methotrexate in children with acute lymphoblastic leukemia N Jebabli, E Gaïes, I Salouage, S Trabelsi, H El jebari, M Lakhal, Anis Klouz, (Tunisia) 68 Tuesday 20 July ■ 09:30 - 12:15 ■ Meeting Room 18/19
FC08 Development in the treatment of sexual dysfunction and diseases of the lower urinary tract Leaders: Karl-Erik Andersson, (USA) & Francois Giuliano, (France) FC08.2 Pharmacological treatment of lower urinary tract syndrome/benign prostatic hyperplasia Chairs: Karl-Erik Andersson, (USA) & Francois Giuliano, (France) 09:30 - 09:55 FC08.2.1 Central pharmacological targets for the treatment of ejaculatory disorders Francois Giuliano, (France) 09:55 - 10:20 FC08.2.2 Sensory functions as a basis for symptoms and therapy in the overactive bladder Karl-Erik Andersson, (USA) 10:20 - 10:45 FC08.2.3 GnRH antagonists – from basic science to the clinic in BPH and lower urinary tract symptoms (LUTS) Enrico Colli, (Denmark) 10:45 - 11:15 COFFEE BREAK 11:15 - 11:40 FC08.2.4 BPH – beyond alpha-adrenoceptors and 5a-reductase Christian Gratzke, (Germany) 11:40 - 11:55 FC08.2.5 Free Communication Presentation: Hypoxic vasodilatation of penile arteries: involvement of nitric oxide (NO) and modulation by reactive oxygen species (ROS) Dolores Prieto, (Spain), P Kaminski, M Ahmad, MS Wolin 11:55 - 12:10 FC08.2.6 Free Communication Presentation: Loss of balance between excitatory P2X3 and inhibitory A1 receptors contribute to cholinergic hyperactivity in the obstructed human bladder Miguel Silva-Ramos, (Portugal), I Silva, M Duarte-Araújo, T Magalhães-Cardoso, J Lafuente-de-carvalho, P Correia-de-Sá Tuesday 20 July ■ 09:30 - 12:15 ■ Meeting Room BV 1/2/3 69
Page 1:
of basic and clinical pharmacology
Page 4 and 5:
Congress patron 2 HRH Crown Princes
Page 6 and 7:
Congress President Kim Brøsen Secr
Page 8 and 9:
General information Registration &
Page 10 and 11:
Banks, currency & credit cards The
Page 12 and 13:
Information to presenters ■ The a
Page 14 and 15:
Hotel Bella Center Copenhagen Groun
Page 16 and 17:
Programme at a glance Time Hall A2
Page 18 and 19:
16 General events General events Op
Page 20 and 21: Programme outline Plenary lectures
Page 22 and 23: FC10 Drugs for half the world: Paed
Page 24 and 25: Tue 12:45 W13 Workshop: Novel perip
Page 26 and 27: W01 Pharmacology of adrenoceptors:
Page 28 and 29: W02 Symposium on advances in GI pha
Page 30 and 31: W04 Symposium: Antioxidants as ther
Page 32 and 33: Plenary lectures PL01 Plenary lectu
Page 34 and 35: FC02 Transmembrane transport: Persp
Page 36 and 37: FC04 Pharmacoepidemiology, current
Page 38 and 39: FC06 The heart gone wrong: Stabiliz
Page 40 and 41: FC09 Inflammation and immunopharmac
Page 42 and 43: W02 Symposium on advances in GI pha
Page 44 and 45: SS01 Sponsored symposium Sponsored
Page 46 and 47: W06 Workshop. Effect of disease on
Page 48 and 49: W08 Workshop. Identifying targets f
Page 50 and 51: W10 Workshop. Innovative Medicines
Page 52 and 53: FC01 Clinical pharmacology in the e
Page 54 and 55: FC03 Ion channels in analgesia and
Page 56 and 57: FC05 Translational science in the m
Page 60 and 61: FC08 Development in the treatment o
Page 62 and 63: Plenary lectures PL04 Plenary lectu
Page 64 and 65: FC01 Clinical pharmacology in the e
Page 66 and 67: FC03 Ion channels in analgesia and
Page 68 and 69: FC05 Translational science in the m
Page 72 and 73: FC09 Inflammation and immunopharmac
Page 74 and 75: W12 Workshop. Experimental pain met
Page 76 and 77: W14 Workshop. Translating the human
Page 78 and 79: W15 Workshop. The IUPHAR initiative
Page 80 and 81: W17 Workshop. Standards for PhD Edu
Page 82 and 83: W19 Workshop. Influence of degenera
Page 84 and 85: FC02 Transmembrane transport: Persp
Page 86 and 87: FC04 Pharmacoepidemiology, current
Page 90 and 91: FC08 Development in the treatment o
Page 92 and 93: PL10 ASPET Plenary Lecture Chair: T
Page 94 and 95: FC10 Drugs for half the world: Paed
Page 96 and 97: FC12 Ion channelopathies: New windo
Page 98 and 99: FC14 Addiction and doping: Neurobio
Page 100 and 101: FC17 New approaches and targets in
Page 102 and 103: W04 Symposium: Antioxidants as ther
Page 104 and 105: W21 Workshop. Inflammation - here,
Page 106 and 107: W23 Workshop. Applying pharmacogeno
Page 108 and 109: W25 Workshop. High science in the l
Page 110 and 111: W27 Workshop. Approaches to medicin
Page 112 and 113: FC11 G protein-coupled 7TM receptor
Page 114 and 115: FC13 Maximising benefits and minimi
Page 116 and 117: FC15 Endothelium in Health and dise
Page 118 and 119: FC17 New approaches and targets in
Page 120 and 121:
FC18 Nuclear receptor targets for t
Page 122 and 123:
PL16 Plenary Lecture Supported by a
Page 124 and 125:
FC11 G protein-coupled 7TM receptor
Page 126 and 127:
FC13 Maximising benefits and minimi
Page 128 and 129:
FC15 Endothelium in Health and dise
Page 130 and 131:
FC17 New approaches and targets in
Page 132 and 133:
W28 Workshop. The Boehringer-Ingelh
Page 134 and 135:
W30 Workshop. Is eNOS still a valid
Page 136 and 137:
W32 Workshop. The good, the bad and
Page 138 and 139:
W34 Workshop. State-of-the-art of b
Page 140 and 141:
FC10 Drugs for half the world: Pedi
Page 142 and 143:
FC12 Ion channelopathies: New windo
Page 144 and 145:
FC14 Addiction and doping: Neurobio
Page 146 and 147:
FC16 Natural products: Past and fut
Page 148 and 149:
Page 150 and 151:
PL22 Plenary Lecture Chair: Zhi-Bin
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
FC15 Endothelium in health and dise
Page 158 and 159:
Page 160 and 161:
158
Page 162 and 163:
FC01 Clinical pharmacology in the e
Page 164 and 165:
Page 166 and 167:
FC02 Transmembrane transport: Persp
Page 168 and 169:
FC03 Ion channels in analgesia and
Page 170 and 171:
W12 Experimental pain methods in de
Page 172 and 173:
FC04 Pharmacoepidemiology, current
Page 174 and 175:
FC05 Translational science in the m
Page 176 and 177:
Page 178 and 179:
FC06 The heart gone wrong; stabiliz
Page 180 and 181:
FC07 Simulation and data modelling
Page 182 and 183:
FC08 Developments in the treatment
Page 184 and 185:
FC09 Inflammation and immunopharmac
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
W03 Targeting TRP channels for pain
Page 196 and 197:
W19 Influence of degeneration and r
Page 198 and 199:
W19 Influence of degeneration and r
Page 200 and 201:
W20 Pharmacology education for a su
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
FC04 Pharmacoepidemiology, current
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
FC06 The heart gone wrong; stabiliz
Page 216 and 217:
FC07 Simulation and data modelling
Page 218 and 219:
FC08 Developments in the treatment
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
FC19 General session Tue 361 Analge
Page 232 and 233:
FC19 General session - Biologics Tu
Page 234 and 235:
FC19 General session - Haematology
Page 236 and 237:
FC19 General session - oncology Tue
Page 238 and 239:
FC19 General session - oncology Tue
Page 240 and 241:
FC19 General session - Toxicology T
Page 242 and 243:
W02 Symposium on advances in GI pha
Page 244 and 245:
W11 New opportunities in the pharma
Page 246 and 247:
W23 Applying pharmacogenomics (PGX)
Page 248 and 249:
FC10 Drugs for half the world: Paed
Page 250 and 251:
Page 252 and 253:
Page 254 and 255:
FC12 Ion channelopathies: New windo
Page 256 and 257:
Page 258 and 259:
Page 260 and 261:
Page 262 and 263:
Page 264 and 265:
Page 266 and 267:
Page 268 and 269:
W30 Is eNOS Still a valid therapeut
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
W34 State-of-the-art of basic and c
Page 282 and 283:
FC10 Drugs for half the world: Paed
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
Page 290 and 291:
Page 292 and 293:
Page 294 and 295:
W29 New horizons in therapeutic dru
Page 296 and 297:
Page 298 and 299:
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
Page 312 and 313:
Page 314 and 315:
Page 316 and 317:
314 Index Name Paper ref. Name Pape
Page 318 and 319:
Page 320 and 321:
Page 322 and 323:
Page 324 and 325:
Page 326 and 327:
Page 328 and 329:
Page 330 and 331:
Page 332 and 333:
Page 334 and 335:
Page 336 and 337:
Page 338 and 339:
Page 340 and 341:
Page 342 and 343:
Page 344 and 345:
Page 346 and 347:
Page 348 and 349:
Page 350 and 351:
Page 352 and 353:
Page 354 and 355:
Page 356 and 357:
Page 358 and 359:
Page 360 and 361:
Page 362 and 363:
Page 364 and 365:
Page 366 and 367:
Page 368 and 369:
Page 370 and 371:
Page 372 and 373:
Page 374 and 375:
Page 376 and 377:
Page 378 and 379:
Page 380 and 381:
Page 382 and 383:
Page 384 and 385:
382 Notes Notes
Page 386:
Final Programme printed in Singapor
show all

Final Programme - iuphar

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?